Can I stop taking Elafibranor midway?

When using elafibranor (Elafibranor) to treat diseases such as non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), many patients are concerned about whether the drug can be stopped midway. First of all, it should be clear that elafibratenol, as an agonist that acts on PPARα/δ, usually needs to be used continuously for a period of time to exert its maximum therapeutic effect. Hasty interruption of medication may affect disease control and even lead to disease rebound or progression.

Ilafibratenol is not a quick-acting drug, and its efficacy is usually gradually manifested through long-term regulation of liver metabolism and inflammatory response. If the patient stops taking the drug without completing a complete course of treatment, he or she may not see the desired effect or miss the opportunity to improve the pathological condition. Therefore, patients should not discontinue medication on their own unless serious adverse reactions occur or unless specifically directed by their physician.

Some patients may experience minor side effects during use, such as gastrointestinal discomfort, fatigue, or mild elevation of aminotransferases. In this case, they should inform their doctor as soon as possible, and the doctor will evaluate whether the dosage needs to be adjusted or the medication needs to be temporarily discontinued. Doctors will comprehensively judge whether to continue medication or change the regimen based on the patient's condition stability, changes in liver function and other indicators.

If it is really necessary to stop taking the drug, it should be done step by step under the guidance of a doctor, and regular follow-up and condition monitoring should be done. Sudden interruption of irafibratenol may disrupt the original treatment plan, especially for patients with primary biliary cholangitis, and the long-term regulatory effect of the drug on cholestasis and inflammation cannot be interrupted. Therefore, patients should maintain close communication with their doctors to ensure safe and reasonable medication management.

Reference materials:https://www.drugs.com/donanemab.html